Table 2.
Treatment for the first progression of primary GBM according to IDH1 mutation status
| Variable | Result | IDH1 mutation status | P value | |
|---|---|---|---|---|
| wtIDH1 GBM (n = 125) | mIDH1 GBM (n = 11) | |||
| Number of cases (%) | Number of cases (%) | |||
| First progression | Progression/progression-free | 106 (84.8)/4 (3.2) | 5 (45.4)/3 (27.3) | 0.053 |
| Censored | 15 (12.0) | 3 (27.3) | ||
| Treatment for first progression | Received/not received | 71 (67.0)/35 (33.0) | 5 (100)/0 | 0.177 |
| Surgery | 18 (25.4) | 2 (40.0) | 0.396 | |
| Re-radiotherapy (RT) | 27 (21.6) | 0 (0.0) | ||
| (Re-RT alone) | 11 (45.5) | 0 (0.0) | ||
| Chemotherapy | 60 (84.5) | 5 (100) | 0.447 | |
| (TMZ) | 18 (25.4)* | 3 (60.0) | ||
| (BEV) | 14 (19.7)* | 0 (0.0) | ||
| (Platinum-based) | 11 (15.5) | 0 (0.0) | ||
| (ACNU-based) | 6 (8.5) | 1 (20.0) | ||
| (ddTMZ) | 4 (5.6) | 0 (0.0) | ||
| (BEV + ACNU) | 3 (4.2) | 1 (20.0) | ||
| (Others) | 4 (5.6) | 0 (0.0) |
ddTMZ, dose-dense temozolomide.
*Containing a case treated by BEV combined with TMZ.